AsclepiX Therapeutics
Manufacturing · Maryland, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
301 W 29th St Ste 2004, Baltimore, Maryl...Phone Number
(412) 327-9499Website
www.asclepix.comRevenue
$5.7 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About AsclepiX Therapeutics
AsclepiX Therapeutics, Inc. is a biopharmaceutical company using computational biology to identify potent peptide regulators of vascular homeostasis that is disrupted in ocular and oncologic diseases. The novel clinical candidate peptides discovered by AsclepiX tap into these naturally existing self-regulating mechanisms, evolved over millions of years, that the body uses to maintain homeostasis and thus restore and maintain health. AXT107, an investigational product candidate and the lead clinical candidate, has a unique mechanism of action that targets two clinically proven pathways of diseases of the retina.Explore more
AsclepiX Therapeutics Org Chart
KB
Chief Executive Officer & Founding Board Memb...
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is AsclepiX Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
AsclepiX Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at AsclepiX Therapeutics
Check if AsclepiX Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if AsclepiX Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once AsclepiX Therapeutics has new funding data
Click to see if AsclepiX Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on AsclepiX Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when AsclepiX Therapeutics launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to AsclepiX Therapeutics
Compare insights from companies similar to AsclepiX Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
AsclepiX Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
AsclepiX Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about AsclepiX Therapeutics.
AsclepiX Therapeutics financials insights
Gather financial insights about AsclepiX Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Other Financing Round
$5M
2020
Series A
$35M
AsclepiX Therapeutics Tech Stack
A closer look at the technologies used by AsclepiX Therapeutics
Most Recent Scoops
Executive Move
Executive Moves, Board of Directors
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
New Hire
Executive Move
New Hire
Executive Move
AsclepiX Therapeutics News & Media
AsclepiX Therapeutics Raises $10 Million to Advance Phase 1/2a Clinical Study of AXT107
Perceptive Advisors leads round to execute study in patients with wet age-related macular degeneration (wet AMD)...AsclepiX appoints Dr. Amir Shojaei as Chief Scientific Officer and Executive Vice President, Clinical Development
Shojaei brings over two and a half decades of experience in clinical pharmaceutical development Shojaei brings over two and a half decades of experience in clinical pharmaceutical developmentAsclepiX Therapeutics, Inc. Appoints Robert J. Dempsey as Chief Executive Officer and President
Pharmaceutical Industry Veteran Further Strengthens the Executive Team BALTIMORE, MD / ACCESSWIRE / March 17, 2021 / AsclepiX Therapeutics, Inc., a biopharmaceutical company using computational biology to identify potent peptide regulators of vascular and cellular homeostasis for the treatment of retinal and oncologic diseases, today announced the appointment of Robert J. Dempsey as Chief Executive Officer and President. Mr. Dempsey bringsAsclepiX Emerges With $35M and an Eye Drug Challenger to Eylea, Lucentis
The body’s natural process for healing wounds has led AsclepiX Therapeutics to a novel approach to treating diseases of the eye. The startup is now gearing up to test its technology in humans, and it has raised $35 million in Series A financing to support its research. Cuts and scrapes in the skin spark the […]
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding AsclepiX Therapeutics
Sign Up For FreeTo access detailed company insights
AsclepiX Therapeutics, Inc. is a biopharmaceutical company using computational biology to identify potent peptide regulators of vascular homeostasis that is disrupted in ocular and oncologic diseases. The novel clinical candidate peptides discovered by AsclepiX tap into these naturally existing self-regulating mechanisms, evolved over millions of y... Read More
